{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:18:12Z","timestamp":1753888692402,"version":"3.41.2"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":179,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Canadian Respiratory Journal"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p><jats:italic>Objectives<\/jats:italic>. We explored the prognostic utility of the unique combination of C\u2010reactive\u2010protein\u2010to\u2010albumin ratio (CAR) and significant weight loss (WL\u2009&gt;\u20095%) over the preceding 6\u2009months, namely, the CARWL score, in stage IIIC non\u2010small\u2010cell lung cancer (NSCLC) patients who underwent concurrent chemoradiotherapy (CCRT). <jats:italic>Methods<\/jats:italic>. For each patient, the CAR was calculated using C\u2010reactive protein and albumin measurements obtained on the first day of CCRT: CAR\u2009=\u2009C\u2010reactive protein\u2009\u00f7\u2009albumin. The availability of an ideal CAR cutoff that may categorize patients into two distinct progression\u2010free (PFS) and overall survival (OS) outcomes was explored by employing receiver operating characteristic (ROC) curve analysis. Patients were additionally divided into two groups based on their status of significant WL according to the well\u2010recognized Delphi criteria. Then, the CARWL score was created by combining all feasible combinations of the CAR and significant WL groupings. The potential links between pretreatment CARWL groups and the post\u2010CCRT OS and PFS outcomes were determined as the primary and secondary endpoints. <jats:italic>Results<\/jats:italic>. This retrospective cohort study comprised a total of 651 stage IIIC NSCLC patients. ROC curve analysis indicated that rounded 3.0 was the ideal CAR cutoff (area under the curve (AUC): 70.1%; sensitivity: 67.8%; specificity: 65.9%), which categorized the patients into CAR\u2009&lt;\u20093.0 (<jats:italic>N<\/jats:italic>\u2009=\u2009324) and CAR\u2009\u2265\u20093.0 (<jats:italic>N<\/jats:italic>\u2009=\u2009327) groups. There were 308 (47.3%) and 343 (52.7%) patients without and with significant WL, respectively. The created CARWL groups were CARWL\u20100: CAR\u2009&lt;\u20093.0 and WL\u2009\u2264\u20095.0%; CARWL\u20101: CAR\u2009&lt;\u20093.0 and WL\u2009&gt;\u20095.0%, or CAR\u2009\u2265\u20093.0 and WL\u2009\u2264\u20095.0%; and CARWL\u20102: CAR\u2009&gt;\u20093.0 and WL\u2009&gt;\u20095.0%. The Kaplan\u2013Meier curves showed that the PFS (14.2 vs. 11.4 vs. 7.5\u2009months; <jats:italic>P<\/jats:italic> &lt; 0.001) and OS (37.3 vs. 23.6 vs. 12.8\u2009months; <jats:italic>P<\/jats:italic> &lt; 0.001) durations were gradually and significantly lowered from the CARWL\u20100 to CARWL\u20102 groups. The CARWL score\u2019s significant impacts on PFS and OS outcomes were found to be independent of the other variables in the multivariate analysis (<jats:italic>P<\/jats:italic> &lt; 0.001, for each). <jats:italic>Conclusions<\/jats:italic>. Our findings indicate that the novel CARWL score, which accounts for pretreatment CAR and significant WL during the preceding 6\u2009months, can reliably stratify newly diagnosed stage IIIC NSCLC patients into three groups with significantly different PFS and OS after definitive CCRT.<\/jats:p>","DOI":"10.1155\/2024\/2803044","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T11:19:56Z","timestamp":1719573596000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Novel CARWL Score in Stage IIIC Non\u2010Small\u2010Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy"],"prefix":"10.1155","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8120-7123","authenticated-orcid":false,"given":"Erkan","family":"Topkan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5361-364X","authenticated-orcid":false,"given":"Ahmet","family":"Kucuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3265-2797","authenticated-orcid":false,"given":"Duriye","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-3756","authenticated-orcid":false,"given":"Emine Elif","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Ayberk","family":"Besen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-488X","authenticated-orcid":false,"given":"Berrin","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8087-3140","authenticated-orcid":false,"given":"Ugur","family":"Selek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"e_1_2_11_1_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj117"},{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1999.17.9.2692"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr325"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.26.2543"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000021455"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)71207-0"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709937"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2009.11.017"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00851-8"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(88)80766-x"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00754"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1986.251.6.c928"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060775"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-9-69"},{"key":"e_1_2_11_15_2","unstructured":"FreyA. MartinD. D\u2032CruzL. FokasE. R\u00f6delC. andFleischmannM. C-Reactive protein to albumin ratio as prognostic marker in locally advanced non-small cell lung cancer treated with."},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2018.10.014"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.52.2.72"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(00)00801-4"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s7101"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70218-7"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2008.06.013"},{"volume-title":"International Mediterranean Scientific Research and Innovation Congress","year":"2022","author":"Kucuk A.","key":"e_1_2_11_22_2"},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.07.033"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.06.025"},{"key":"e_1_2_11_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2021.06.140"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.09.009"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1326-1"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2011.00052"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2007.12.001"}],"container-title":["Canadian Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2024\/2803044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T11:20:05Z","timestamp":1719573605000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2024\/2803044"}},"subtitle":[],"editor":[{"given":"Jack","family":"Kastelik","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1155\/2024\/2803044"],"URL":"https:\/\/doi.org\/10.1155\/2024\/2803044","archive":["Portico"],"relation":{},"ISSN":["1198-2241","1916-7245"],"issn-type":[{"type":"print","value":"1198-2241"},{"type":"electronic","value":"1916-7245"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2803044"}}